African Americans are a genetically diverse population with a high burden of many, common heritable diseases. However, our understanding of genetic variation in African Americans is substandard because of a lack of published population-based genetic studies. We report the distribution of copy-number variation (CNV) in African Americans collected as part of the Hypertension Genetic Epidemiology Network (HyperGEN) using the Affymetrix 6.0 array and the CNV calling algorithms Birdsuite and PennCNV. We present population estimates of CNV from 446 unrelated African-American subjects randomly selected from the 451 families collected within HyperGEN. Although the majority of CNVs discovered were individually rare, we found the frequency of CNVs to be collectively high. We identified a total of 11 070 CNVs greater than 10 kb passing quality control criteria that were called by both algorithms -leading to an average of 24.8 CNVs per person covering 2214 kb (median). We identified 1541 unique copy-number variable regions, 309 of which did not overlap with the Database of Genomic Variants. These results provide further insight into the distribution of CNV in African Americans.
INTRODUCTION
Genome-wide association studies based on single-nucleotide polymorphisms have been modestly successful in identifying genetic correlates of phenotypic variation for many complex disorders, including psychiatric, autoimmune, and cardiovascular traits. 1 However, much of the genetic variance attributed to these diseases remains unexplained. Copy-number variation (CNV) has been cited as a potential source of genetic variation, contributing to the development of complex diseases, potentially through rare variation driven by purifying selection acting on exonic and intronic deletions. 2, 3 Redon et al 4 constructed a first-generation map of CNV in the human genome from 270 individuals in the HapMap collection. 5 They found over 1400 copy-number variable regions (CNVRs) covering roughly 12% of the genome. These regions overlapped with over half of the known reference sequence genes. Other early studies examined CNV in different racial/ethnic populations -including unrelated healthy individuals from Northern Germany, 6 Caucasian males from Northern France, 7 and Koreans 8 among others -many of which are included in the Database of Genomic Variants (DGVs). 9 Yet there remains a lack of published genome-wide data on CNV in African Americans -a racial/ethnic group with a particularly high burden of many common, heritable diseases that occur within numerous biological pathways, including cardiovascular diseases such as hypertension and stroke, 10 metabolic disorders such as type 2 diabetes 11 and kidney disease, 12 and autoimmune and neurological disorders such systemic lupus erythematosus 13 and Alzheimer's disease. 14 Only one such study has investigated CNVs exclusively in African Americans. 15 This study identified 1362 copy-number variants in 385 African Americans using the Affymetrix Genome-Wide SNP Array 5.0 (Affymetrix, Santa Clara, CA, USA). However, the continued development of CNV genotyping platforms and statistical calling algorithms dictates the routine reevaluation of the distribution of CNV on a genome-wide level.
In this study we examined CNVs in an unrelated sample of AfricanAmerican individuals derived from 451 families in the Hypertension Genetic Epidemiology Network (HyperGEN) who were genotyped on the Affymetrix Genome-Wide SNP Array 6.0. This platform was specifically designed in consideration of CNV and provides a more accurate assessment of CNV compared with its predecessor in terms of copy-number probe density, measurement reliability, and detection. 16 CNVs were inferred using the normalization procedures and calling applications in Birdsuite 16 and PennCNV. 17 We present the genomewide distribution of CNV. In particular, we have focused on the size and location of CNV, and distinguish between known and novel CNVRs. Our work provides further insight into specific structural variation in African Americans.
METHODS

Data set
Study participants were obtained from the HyperGEN Study. HyperGEN is one of four Family Blood Pressure Program networks supported by the National Heart, Lung, and Blood Institute to identify genetic contributors to hypertension. 18 In the first phase of the HyperGEN Study, hypertensive sibships eligible for recruitment consisted of probands, with onset of hypertension by age 60 years and one or more hypertensive siblings who were willing to participate in the study. In the second phase of the study, the offspring of the hypertensive siblings were recruited. Hypertension was defined as having an average systolic blood pressure Z140 mm Hg or average diastolic blood pressure Z90 mm Hg during at least two evaluations or receiving medical treatment for hypertension.
The HyperGEN Study includes 1549 African-American subjects recruited from centers located in Birmingham, AL, USA, and Forsyth County, NC, USA. Cardiovascular-related phenotypes were measured on the subjects, such as laboratory measurements, blood pressure, body mass index, left ventricular wall thickness, and pulse pressure/stroke volume ratio among others. These phenotypic characteristics have been extensively studied elsewhere. A number of positive genetic associations with these phenotypes have been reported including the MYH9 gene and albuminuria, 19 the KCNB1 gene and left ventricular mass, 20 and the CRCP gene and aortic root diameter. 21 
Genotyping methods
Genetic data were obtained from 1224 HyperGEN African-American subjects from 451 families via the Affymetrix Genome-Wide Human SNP Array 6.0. DNA samples were processed in 34 batches, in which one batch consisted of all the samples that were processed on a particular day (average batch size¼36). The Affymetrix genotyping protocol was followed.
CNV analysis
CNV calling algorithms can often produce discrepant results on the same data set. These inconsistencies can occur due to the process by which samples are normalized and compared with a reference genome, the type of calling algorithm used, and deviation in the parameters between similar types of algorithms. 22 Recent CNV studies have supported a stringent discovery criterion of only reporting copy-number segments that are similarly identified by at least two different algorithms. 23 This standard increases the confidence of identified CNVs. Therefore, copy-number calls were made using Birdsuite 16 and PennCNV 17 software. In general, confidence thresholds implemented in the algorithms were set as close to the developers' default values or references as possible. Genetic samples obtained from small batches (three batches with less than 10 samples each), or that did not meet quality control criteria in either algorithm, were removed from further analysis. Among the remaining samples, one participant from each family was randomly selected to be included in downstream analysis (N¼446). The findings of this paper include only copynumber segments 410 kb in autosomes. Results using differing probe counts as an alternative to segment length were explored, but found them to be inferior in terms of agreement between the calling algorithms (Supplementary Table 1 ).
Birdsuite
Birdsuite version 1.5.5 was used for copy-number analysis. 16 Samples were processed by batch to eliminate batch effects. This allows for better clustering of the data and improves sensitivity and specificity of the algorithm compared with combining data across batches. Samples with copy-number sample variances greater than two were removed from downstream analysis. Copynumber events were measured using the Hidden Markov Model (HMM)-based Birdseye application, using segments with LOD values 45.0 to indicate a positive call. Output files were processed with version 1.4 of the Birdsuite to PLINK Pipeline 24 and summarized using the CNV applications in PLINK version 1.05 where appropriate. 25 
PennCNV
CNVs were also called using the PennCNV algorithm, 17 which takes into consideration the total signal intensity and allelic intensity ratio at each SNP marker, the distance between neighboring SNPs, and the allele frequency of each SNP through a HMM. All samples were processed simultaneously. The PennCNV-Affymetrix protocol (http://www.openbioinformatics.org/penncnv/ penncnv_tutorial_affy_gw6.html) was first applied to transform the intensities from the raw CEL files into log R ratios (LRRs) and B allele frequencies (BAFs) on all samples. We used the developer's default settings for the HMM, and also applied the model adjustment for genomic waves. 26 We removed noisy samples from downstream analyses based on previously used criteria for quality control: 27 standard deviation for autosomal LRR40.28, a median BAF of 40.55 or o0.45 or a BAF drift of 40.002.
Verification and comparison procedures
Both the Birdseye application in Birdsuite and PennCNV are five-state HMMs that produces results at a given probe by estimating the integer copy-number state as 0 copies, 1 copy, 2, 3, or 4 copies. This allows for greater accuracy in predicting SNP allele counts in CNVRs as opposed to more traditional CNV calling algorithms, which simply use 'loss' , 'normal' , or 'gain' . However, in terms of comparing CNV calls between Birdsuite and PennCNV, we combined 0 and 1 copy calls and refer them as deleted segments, 3 and 4 copy calls as duplicated segments, and 2 copies as normal. This allowed the comparison between algorithms to not be overly conservative. For example, if Birdsuite assigned a copy number of 3 to a given locus and PennCNV assigned a copy number of 4 to that locus, then we concluded that both algorithms assigned 'duplication' to this region. For CNVs in which both algorithms made similar calls and had at least one base pair overlap, we assumed they were calling the same segment.
A similar concern is the overlap of CNV calls across individuals, as there is often ambiguity in terms of the exact break points of a CNV. We defined CNVRs as the region starting at the first base pair of all overlapping deleted or duplicated segments across samples (at least one base pair) and ending at the last base pair of these segments. After localizing these CNVRs, we compared these with known copy-number variants in the DGVs. 9 We considered a CNVR to be novel if it did not overlap with any of the CNVs included in this database at the time of preparation of this manuscript.
We validated one CNVR called by both algorithms using quantitative PCR (qPCR). This CNVR was a common duplicated region identified on chromosome 3: 46 738 146-46 855 144. This region overlaps portions of the PRSS50 and PRSS42 genes, and completely encompasses the PRSS45 gene. We selected premade and commercially available qPCR probes as provided by Applied Biosystems Inc. (Foster City, CA, USA) in this region (Figure 1) . These probes have been tested by the vendor and performed according to their specifications for CNV testing. Samples were diluted to 5 ng/ml, and 2 ml of each sample was used for each reaction. A real-time PCR reaction was set up using Genotyping Master Mix (ABI Cat no.: 4371355), RNase P, the probe, and water. Each sample was set up in quadruplicate. The standard real-time PCR protocol on the ABI 7900 was used. A set of cases (n¼50, defined as participants having more than two copies in this region identified by Birdsuite and PennCNV) and eight controls (two copies) were analyzed. The controls were selected from HyperGEN Cohort showing only two copies of the alleles for the probes covering PRSS45 gene in the initial array analyses. For each probe in this region, we verified that controls had two copies. Cases and controls were randomly placed on each plate. Sample analysis on the instrument was performed using manual baseline set at 0.2. Data were exported and analyzed with Applied Biosystem's copy-number macro to determine the copy-number state.
HyperGEN includes genetic information and a variety of phenotypic data on hypertensive siblings and their offspring. The long-term goals of this study are to determine which genes may be responsible for a multitude of cardiovascular-related traits. Knowing the extent to which CNV is present in known genes may influence the way future association testing in HyperGEN and other studies are designed when considering both SNPs and CNVs. To accomplish this, we constructed a record of known genes from the UCSC and Entrez gene databases based upon the Human Genome 18 reference map and compared our CNV calls with this list. 28, 29 
RESULTS
We identified 1541 unique CNVRs identified by both Birdsuite and PennCNV, of which 309 were novel. There were differences in the total number of deleted and duplicated segments called by each algorithm. We found a total of 14 522 and 10 529 deleted segments and 6014 and 5631 duplicated segments using Birdsuite and PennCNV, respectively. These values equate to 32.5 and 24.2 deleted segments, and 13.5 and 12.6 duplicated segments per person found in Birdsuite and PennCNV, respectively. We identified 11 070 CNVs that were called by both algorithms (Figure 2 ), including 8385 deletions and 2685 duplications -an agreement of 79.6% and 47.7% between algorithms, respectively. These segments covered a total genomic area of 2214 kb per person (median). Perhaps not surprisingly, duplicated segments tended on average to be larger than deleted segments. Among the CNVRs identified by both algorithms, 655 were present in more than one individual (see Supplementary Table 2 for complete CNVR results and a comparison with regions recognized in the DGVs 9 and Conrad et al 3 ).
One of our conditions for CNV detection was the inclusion of only copy-number segments that were larger than 10 kb. The smallest CNV we discovered that was identified by both algorithms was a deleted segment, 10 007 bp in length and located on chromosome 2. Meanwhile, the largest CNV identified by both algorithms was a deleted segment, 21.6 Mb in length and located on chromosome 1. We discovered more small CNVs than larger ones (Table 1 ). The median length deletions called by both algorithms was 36.6 kb and the median length of duplication was 94.8 kb. The median length of CNV regardless of deletion or duplication identified by both algorithms was 42.3 kb.
The majority of CNVRs that were called by both Birdsuite and PennCNV were rare (77.7%), occurring in o1% of the study population (four or less individuals). Many CNVRs were singleton (57.6%), only occurring in one individual ( Table 2 ). The most common CNVR was a deletion present in 214 individuals and located on chromosome 1: 194 994 473-195 176 268 bp. This CNVR falls within the CFHR3 region that has previously been shown to be associated with age-related macular degeneration. 30 Common CNVs were present in all the chromosomes, although the amount of regions with common CNVs did not appear to be uniform (Figure 3) . The majority of novel CNVRs were only present in one person (87.7%), considerably higher than the frequency of singleton CNVRs intersecting known regions (49.9%). The most common, novel CNVR was a deletion on chromosome 8: 53 035 013-53 082 676 bp that overlaps the LOC286071 gene. Another equally common, novel CNVR was a duplication on chromosome 16: 5 456 063-5 468 535 bp. However, CNVs in both regions were only observed in five individuals. All novel CNVRs we detected in three or more individuals are listed in Table 3 .
The duplication we validated by qPCR in the PRSS45 region on chromosome 3 was confirmed in all 50 cases. For most subjects, we were only able to confirm the location of one break point, as the amplification appeared to stretch beyond the Q5 probe (Figure 1) . The break point that we were able to confirm occurred between the Q2 and Q3 probes in 38 of the 50 cases. Among the other 12 subjects, 10 had the break point occurring between Q3 and Q4, one between Q1 and Q2, and the remaining one missing. In 45 of the 50 cases, the amplification was witnessed in three copies. In four of the other five subjects, the amplification began as a three-copy duplication and increased to four copies at the Q5 probe. The remaining subject had a four-copy duplication, seen only at the Q4 probe.
Many of the CNVs called by PennCNV and Birdsuite overlapped known genes referenced in the Entrez and UCSC gene databases. Ignoring the type of CNV, there did not appear to be a considerable Our results should be interpreted within the context of a number of limitations. Given the sample ascertainment scheme based on hypertensive status, it is possible that our sample may overestimate the population distribution of CNVs assuming a role of CNV in the development of hypertension. Also, the HyperGEN Cohort consists of Caucasian participants in addition to the African-American participants used in the present study. Unfortunately, Caucasian participants were genotyped before the African-American participants and before the Affymetrix 6.0 array became available. As a result, we were unable to compare CNV differences across racial group without confounding the results by array differences. In addition, although we chose to report CNVs on only unrelated subjects, the use of family data can provide interesting results particularly in identifying de novo CNVs. However, because of the ascertainment scheme of HyperGEN, data were generally only gathered from one parent. Thus we were unable to distinguish between inherited and de novo events. Finally, although the assessment of CNV derived from the Affymetrix 6.0 is a vast improvement over its predecessor, the results presented here are by no means a complete CNV map. Particularly, small CNVs tend to have very high false negative rates and, as was seen in the qPCR experiment we performed, CNV boundaries can vary amongst individuals.
Nevertheless, we found that on a genomic level CNV appeared to be quite common based upon the sheer number of events we witnessed. Among the 1541 unique CNVRs that we identified with both calling algorithms, 655 were present in more than one individual. These regions may include polymorphic CNVs, which can be more directly measured and lend themselves to traditional disease-gene association testing. Furthermore, about a fifth of all the CNVRs that we discovered had not previously been recognized in the DGVs 9 -a few of which were present in multiple subjects. A total of 37 CNVRs that we discovered were present in more than one individual, but were not included in the DGV. This is in contrast to the report by McElroy et al, who found only three CNVs present in two or more individuals, but were not in the DGV. Similar to McElroy et al, we found a high frequency of a duplication on chromosome 15, but did not replicate their observed high frequency of a duplication on chromosome 9. The reason for this lack of replication is unclear, but would not appear to be due to the size restriction imposed by our study. Regions included are those that were present in three or more individuals and not currently in the Database of Genomic Variants.
Many of the CNVRs that we discovered overlapped with known genes. Although potential pathological implications of these CNVRs cannot be determined from this study, the genes STK39 and SLCO4C1 have been implicated in hypertension 31, 32 and DNAH5 with various forms of congenital heart disease. 33 Other genes have been linked to asthma 34 and to various forms of cancer. 35, 36 Future studies would be warranted to determine the association of these novel CNVRs with specific disease states.
Although we were not able to include data from other populations to make a direct inference about relative occurrences of CNV in African Americans, we discovered 309 novel CNVs that did not overlap with CNVRs in the DGV. 9 This provides some evidence that the distribution of CNV in African Americans is at least partially different from that of other populations. Our work provides further insight into the copy-number architecture of African Americans.
